Epizyme Inc. (NASDAQ:EPZM)’s share price rose 2.7% during mid-day trading on Tuesday . The stock traded as high as $7.80 and last traded at $7.72, with a volume of 96,537 shares trading hands. The stock had previously closed at $7.52.

EPZM has been the subject of several analyst reports. Cowen and Company reissued a “buy” rating on shares of Epizyme in a report on Monday, June 20th. Mizuho reissued a “buy” rating and set a $18.00 price target on shares of Epizyme in a report on Monday, June 20th. Royal Bank Of Canada reissued an “outperform” rating and set a $26.00 price target on shares of Epizyme in a report on Monday, June 20th. JMP Securities reissued a “buy” rating and set a $28.00 price target on shares of Epizyme in a report on Thursday, June 23rd. Finally, Leerink Swann reissued an “outperform” rating and set a $39.00 price target on shares of Epizyme in a report on Tuesday, June 21st. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $23.11.

The company’s market capitalization is $423.66 million. The firm has a 50-day moving average price of $9.12 and a 200 day moving average price of $10.33.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. On average, analysts anticipate that Epizyme Inc. will post ($2.19) EPS for the current year.

In related news, insider Robert A. Copeland sold 4,000 shares of the company’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $10.37, for a total value of $41,480.00. Following the transaction, the insider now directly owns 35,538 shares in the company, valued at $368,529.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.